Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Renal Drug Excretion: Tubular Secretion

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Renal Drug Excretion: Overview

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...

Renal Drug Excretion: Tubular Reabsorption

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ischemic injury of the upper gastrointestinal tract after out-of-hospital cardiac arrest: a prospective, multicenter study.

Critical care (London, England)·2022

Same author

[Enteropathy due to olmesartan].

Annales de cardiologie et d'angeiologie·2016

Same author

Olmesartan-associated enteropathy: results of a national survey.

Alimentary pharmacology & therapeutics·2014

Same author

[Hepatitis B reactivation with rituximab in an HIV-infected anti-HBs antibody carrier].

Medecine et maladies infectieuses·2011

Same author

[Gastric metastasis revealing lung cancer].

Gastroenterologie clinique et biologique·2009

Same author

[HCV contamination of endoscopes and biopsy clips].

Annales de biologie clinique·2001

Search research articles

Related Experiment Video

Updated: Apr 10, 2026

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Published on: June 15, 2020

[Enteropathy due to olmesartan].

M Ould Sidi Mohamed¹, P Colardelle¹

¹Centre hospitalier André-Mignot, Versailles, France.

Annales De Cardiologie Et D'Angeiologie

|June 13, 2015

Summary

Olmesartan, a hypertension medication, can cause serious gastrointestinal issues like villous atrophy. This case highlights the importance of considering olmesartan-induced enteropathy in patients with unexplained chronic diarrhea.

Area of Science:

Gastroenterology
Pharmacology

Background:

Olmesartan is a widely prescribed angiotensin II receptor blocker for hypertension.
Gastrointestinal side effects of olmesartan, though rare, are increasingly recognized.

Observation:

A patient developed chronic diarrhea and weight loss after 3 years of olmesartan use.
Endoscopic and biopsy findings revealed duodenal villous atrophy, lymphocytic infiltrate, and erosive esophagitis.

Findings:

Discontinuation of olmesartan led to rapid symptom resolution.
Reintroduction of olmesartan promptly reproduced the gastrointestinal symptoms and histological abnormalities.
Histological examination confirmed duodenal villous atrophy and lymphocytic enteritis.

Implications:

Keywords:

Enteropathy Entéropathies Olmesartan

More Related Videos

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Apr 10, 2026

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Published on: June 15, 2020

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

This case underscores the need for awareness of olmesartan-induced enteropathy among clinicians.
Early recognition and drug withdrawal can prevent severe gastrointestinal complications.
Further research may identify predictive factors for this adverse drug reaction.